JP2023512778A - 栄養補助食品の組成物および方法 - Google Patents
栄養補助食品の組成物および方法 Download PDFInfo
- Publication number
- JP2023512778A JP2023512778A JP2022547864A JP2022547864A JP2023512778A JP 2023512778 A JP2023512778 A JP 2023512778A JP 2022547864 A JP2022547864 A JP 2022547864A JP 2022547864 A JP2022547864 A JP 2022547864A JP 2023512778 A JP2023512778 A JP 2023512778A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- powder
- plant material
- composition
- green
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 313
- 238000000034 method Methods 0.000 title claims abstract description 71
- 235000015872 dietary supplement Nutrition 0.000 title description 7
- 239000000463 material Substances 0.000 claims abstract description 150
- 230000000694 effects Effects 0.000 claims abstract description 101
- 230000005764 inhibitory process Effects 0.000 claims abstract description 99
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 87
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 87
- 230000036541 health Effects 0.000 claims abstract description 14
- 230000007166 healthy aging Effects 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 148
- 241000196324 Embryophyta Species 0.000 claims description 129
- 239000000284 extract Substances 0.000 claims description 81
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 48
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 47
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 46
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 45
- 230000002401 inhibitory effect Effects 0.000 claims description 45
- 102100021257 Beta-secretase 1 Human genes 0.000 claims description 41
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims description 41
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 claims description 37
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims description 37
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 37
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 36
- 230000027455 binding Effects 0.000 claims description 36
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 34
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 34
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 34
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 34
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 34
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 34
- 238000009739 binding Methods 0.000 claims description 34
- 240000007817 Olea europaea Species 0.000 claims description 33
- 229940109529 pomegranate extract Drugs 0.000 claims description 33
- 241000533293 Sesbania emerus Species 0.000 claims description 32
- 229940002508 ginger extract Drugs 0.000 claims description 32
- 235000020708 ginger extract Nutrition 0.000 claims description 32
- 229940038487 grape extract Drugs 0.000 claims description 32
- 229940065115 grapefruit extract Drugs 0.000 claims description 32
- 229940072113 onion extract Drugs 0.000 claims description 32
- 229940092258 rosemary extract Drugs 0.000 claims description 32
- 235000020748 rosemary extract Nutrition 0.000 claims description 32
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 32
- 240000007124 Brassica oleracea Species 0.000 claims description 30
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 30
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 30
- 244000000626 Daucus carota Species 0.000 claims description 30
- 235000002767 Daucus carota Nutrition 0.000 claims description 30
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 30
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 30
- 235000001537 Ribes X gardonianum Nutrition 0.000 claims description 30
- 235000001535 Ribes X utile Nutrition 0.000 claims description 30
- 235000016919 Ribes petraeum Nutrition 0.000 claims description 30
- 244000281247 Ribes rubrum Species 0.000 claims description 30
- 235000002355 Ribes spicatum Nutrition 0.000 claims description 30
- 240000003768 Solanum lycopersicum Species 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 28
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 28
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 27
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 27
- -1 SIRT-1 Proteins 0.000 claims description 27
- 108090000613 Cathepsin S Proteins 0.000 claims description 26
- 102100035654 Cathepsin S Human genes 0.000 claims description 25
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 25
- 235000021537 Beetroot Nutrition 0.000 claims description 24
- 235000019216 blueberry extract Nutrition 0.000 claims description 24
- 229940055416 blueberry extract Drugs 0.000 claims description 24
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 23
- 101100326804 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-2 gene Proteins 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 19
- 229940069765 bean extract Drugs 0.000 claims description 18
- 239000003086 colorant Substances 0.000 claims description 18
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 239000011885 synergistic combination Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 16
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 15
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 13
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 13
- 235000018735 Sambucus canadensis Nutrition 0.000 claims description 13
- 235000007123 blue elder Nutrition 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 235000007124 elderberry Nutrition 0.000 claims description 13
- 235000008995 european elder Nutrition 0.000 claims description 13
- 235000020956 nicotinamide riboside Nutrition 0.000 claims description 13
- 239000011618 nicotinamide riboside Substances 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 235000010755 mineral Nutrition 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 11
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 10
- 235000013406 prebiotics Nutrition 0.000 claims description 10
- 239000006041 probiotic Substances 0.000 claims description 10
- 235000018291 probiotics Nutrition 0.000 claims description 10
- 235000013619 trace mineral Nutrition 0.000 claims description 10
- 239000011573 trace mineral Substances 0.000 claims description 10
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 8
- 239000003150 biochemical marker Substances 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 230000036737 immune function Effects 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 230000007351 Aβ plaque formation Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 230000028709 inflammatory response Effects 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000007000 age related cognitive decline Effects 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 9
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 3
- 244000151637 Sambucus canadensis Species 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 25
- 108090000790 Enzymes Proteins 0.000 abstract description 25
- 230000002195 synergetic effect Effects 0.000 abstract description 16
- 235000001412 Mediterranean diet Nutrition 0.000 abstract description 13
- 230000002255 enzymatic effect Effects 0.000 abstract description 7
- 230000037361 pathway Effects 0.000 abstract description 7
- 230000007407 health benefit Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 94
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000003556 assay Methods 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 28
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 16
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000012131 assay buffer Substances 0.000 description 15
- 238000007405 data analysis Methods 0.000 description 15
- 230000008901 benefit Effects 0.000 description 14
- 238000004020 luminiscence type Methods 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 238000006911 enzymatic reaction Methods 0.000 description 13
- 102100021723 Arginase-1 Human genes 0.000 description 12
- 101710129000 Arginase-1 Proteins 0.000 description 12
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 description 12
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 description 12
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 108010041191 Sirtuin 1 Proteins 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 230000032683 aging Effects 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000208829 Sambucus Species 0.000 description 10
- 241001464837 Viridiplantae Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 244000078534 Vaccinium myrtillus Species 0.000 description 9
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 235000021014 blueberries Nutrition 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000007824 enzymatic assay Methods 0.000 description 7
- 230000035790 physiological processes and functions Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 235000016068 Berberis vulgaris Nutrition 0.000 description 6
- 241000335053 Beta vulgaris Species 0.000 description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 6
- 102000011990 Sirtuin Human genes 0.000 description 6
- 108050002485 Sirtuin Proteins 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000004962 physiological condition Effects 0.000 description 6
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 102000004452 Arginase Human genes 0.000 description 5
- 108700024123 Arginases Proteins 0.000 description 5
- 108010024121 Janus Kinases Proteins 0.000 description 5
- 102000015617 Janus Kinases Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000000198 fluorescence anisotropy Methods 0.000 description 5
- 239000002417 nutraceutical Substances 0.000 description 5
- 235000021436 nutraceutical agent Nutrition 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 4
- 238000003719 Kinase-Glo Plus Luminescent Kinase Assay Methods 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 102000044459 human CD47 Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000007082 Aβ accumulation Effects 0.000 description 2
- 229940127272 CD73 inhibitor Drugs 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710147507 Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KOBHCUDVWOTEKO-VKHMYHEASA-N Nomega-hydroxy-nor-l-arginine Chemical compound OC(=O)[C@@H](N)CCNC(=N)NO KOBHCUDVWOTEKO-VKHMYHEASA-N 0.000 description 2
- 239000009424 Oxxynea Substances 0.000 description 2
- 102100029008 Putative HTLV-1-related endogenous sequence Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 101150036449 SIRPA gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000005189 cardiac health Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000004280 healthy diet Nutrition 0.000 description 2
- AZCSOJKJFMWYCX-UHFFFAOYSA-N hexasodium;dioxido(dioxo)tungsten;trioxotungsten Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.[O-][W]([O-])(=O)=O.[O-][W]([O-])(=O)=O.[O-][W]([O-])(=O)=O AZCSOJKJFMWYCX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000053786 human PCSK9 Human genes 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000911965 Homo sapiens Cyclin-dependent-like kinase 5 Proteins 0.000 description 1
- 101100501552 Homo sapiens ENTPD1 gene Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101000998855 Homo sapiens Nicotinamide phosphoribosyltransferase Proteins 0.000 description 1
- 101000679400 Homo sapiens Tubulin polymerization-promoting protein Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 101150116862 KEAP1 gene Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000219991 Lythraceae Species 0.000 description 1
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 101710112406 Ribosylnicotinamide kinase Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 1
- 101710205336 Steroid hormone receptor ERR1 Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710127774 Stress response protein Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JCDBQDNBEQHDHK-BSLNIGMPSA-N [(2r,3s,4r,5r)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2r,3s,4r,5r)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C5=NC=CN5C=N4)N=C3)O)O2)O)=C1 JCDBQDNBEQHDHK-BSLNIGMPSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- OLCWZBFDIYXLAA-IOSLPCCCSA-N adenosine 5'-methylenediphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O OLCWZBFDIYXLAA-IOSLPCCCSA-N 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000000842 betacyanins Nutrition 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229950009859 dinaciclib Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000021554 flavoured beverage Nutrition 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 102000044297 human BACE1 Human genes 0.000 description 1
- 102000052645 human CD38 Human genes 0.000 description 1
- 102000048957 human CDK5 Human genes 0.000 description 1
- 102000043555 human LDLR Human genes 0.000 description 1
- 102000045309 human NT5E Human genes 0.000 description 1
- 102000051498 human TPPP Human genes 0.000 description 1
- 102000012427 human indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 102000000418 human nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940005741 sunflower lecithin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2132—Other phenolic compounds, polyphenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
実施例
代表的な組成物:
ARG1およびARG2:
SIRT1:
Keap/Nrf2:
ACE2-スパイク:
BACE1:
カテプシンS:
CDK5:
IDO1/IDO2:
NAMPT:
CD38:
JAK1/JAK2/JAK3:
CD39:
CD73:
Claims (70)
- 赤色、緑色、橙黄色、および紫青色を有する植物材料由来の複数の化学的に異なるポリフェノールと組み合わせた、栄養学的に許容される担体を含み、
前記植物材料由来の前記化学的に異なるポリフェノールは、BACE1、CD38、CD73、CDK5、JAK1、JAK2、およびJAK3からなる群から選択される少なくとも1つの生化学的マーカーの阻害に関して相乗的な組み合わせであることを特徴とする栄養組成物。 - 赤色を有する前記植物材料は、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末のうちの少なくとも1つを含み、緑色を有する前記植物材料は、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末のうちの少なくとも1つを含み、橙黄色を有する前記植物材料は、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末のうちの少なくとも1つを含み、紫青色を有する前記植物材料は、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末の少なくとも1つを含む請求項1に記載の組成物。
- 赤色を有する前記植物材料は、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末のうちの少なくとも2つを含み、緑色を有する前記植物材料は、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末のうちの少なくとも2つを含み、橙黄色を有する前記植物材料は、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末のうちの少なくとも2つを含み、紫青色を有する前記植物材料は、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末の少なくとも2つを含む請求項1に記載の組成物。
- 赤色を有する前記植物材料は、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末を含み、緑色を有する前記植物材料は、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末を含み、橙黄色を有する前記植物材料は、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末を含み、紫青色を有する前記植物材料は、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末を含む請求項1に記載の組成物。
- 前記化学的に異なるポリフェノールが、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSからなる群から選択される少なくとも1つの追加の生化学的マーカーをさらに阻害する、請求項1に記載の組成物。
- Keap/Nrf2結合および/またはACE2/Spike結合をさらに阻害する、請求項1に記載の組成物。
- 前記組成物が経口投与用の単一投与単位で処方される、請求項1に記載の組成物。
- 前記単一投与単位が50~1,000mgの前記組成物を含有する、請求項7に記載の組成物。
- 前記単一投与単位が、カプセル、グミ、または粉末として処方される、請求項7に記載の組成物。
- 前記組成物が、ビタミン、食事性微量元素またはミネラル、ニコチンアミドリボシド、プロバイオティクス、および/またはプレバイオティクスをさらに含む、請求項1に記載の組成物。
- 赤色、緑色、橙黄色、および紫青色を有する植物材料由来の複数の化学的に異なるポリフェノールと組み合わせた、栄養学的に許容される担体を含み、
赤色を有する前記植物材料は、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末を含み、
緑色を有する前記植物材料は、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末を含み、
橙黄色を有する前記植物材料は、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末を含み、
紫青色を有する前記植物材料は、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末の少なくとも1つを含み、
前記植物材料の組み合わせは、BACE1、CD38、CD73、CDK5、JAK1、JAK2、およびJAK3からなる群から選択される少なくとも1つの生化学的マーカーの阻害に関して相乗的な組み合わせであることを特徴とする栄養組成物。 - 前記植物材料の前記組み合わせが、BACE1、CD38、およびCD73の阻害に関して相乗的な組み合わせである、請求項11に記載の組成物。
- ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSからなる群から選択される少なくとも1つの追加の生化学的マーカーをさらに阻害する、請求項11に記載の組成物。
- Keap/Nrf2結合および/またはACE2/Spike結合をさらに阻害する、請求項11に記載の組成物。
- 前記組成物が経口投与用の単一投与単位で処方される、請求項11に記載の組成物。
- 前記単一投与単位が50~1,000mgの前記組成物を含有する、請求項15に記載の組成物。
- 前記単一投与単位が、カプセル、グミ、または粉末として処方される、請求項15に記載の組成物。
- 前記組成物が、ビタミン、食事性微量元素またはミネラル、ニコチンアミドリボシド、プロバイオティクス、および/またはプレバイオティクスをさらに含む、請求項15に記載の組成物。
- 前記組成物が、炎症状態、心血管状態、神経学的状態、代謝状態、および癌の症状を治療および/または軽減するのに有効である、請求項11に記載の組成物。
- リンゴ抽出物、ザクロ抽出物、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、ブドウ抽出物、およびブルーベリー抽出物がエタノール抽出物またはエタノール/水抽出物である、請求項11に記載の組成物。
- 個人の健康をサポートする方法であって、請求項1~10または11~20のいずれか一項に記載の組成物を前記個人に投与することを含むことを特徴とする方法。
- 前記組成物が投与されることによって、免疫サポート、代謝サポート、長寿のサポート、中枢神経系(CNS)機能のサポート、炎症反応の軽減、心血管疾患の影響の軽減、およびアミロイドベータプラーク形成率の軽減を提供する、請求項21に記載の方法。
- 前記組成物が少なくとも30日間にわたって経口投与される、請求項21記載の方法。
- 前記組成物が50~1,000mgの1日用量で経口投与される、請求項21に記載の方法。
- ビタミン、食事性微量元素またはミネラル、ニコチンアミドリボシド、プロバイオティクス、および/またはプレバイオティクスを同時投与することをさらに含む、請求項21に記載の方法。
- 前記食事性微量元素または前記ミネラル、前記ニコチンアミドリボシド、前記プロバイオティクス、および/または前記プレバイオティクスが同じ投与単位で同時投与される、請求項25に記載の方法。
- 個人のNAD+減少を低減させる方法であって、
赤色、緑色、橙黄色、および紫青色を有する植物材料由来のポリフェノールの相乗的な組み合わせを個人に投与することを含み、
前記組み合わせはCD38を相乗的に阻害することを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項27に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項27または28に記載の方法。
- 前記NAD+の減少が加齢に伴うNAD+の減少である、請求項27記載の方法。
- 個人の寿命をサポートする方法であって、
赤色、緑色、橙黄色、および紫青色を有する植物材料由来のポリフェノールの相乗的な組み合わせを個人に投与することを含み、
前記組み合わせはCD73を相乗的に阻害することを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項31に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項31または32に記載の方法。
- 前記投与が免疫機能を増大させ、それによって寿命を維持する、請求項31に記載の方法。
- 個人の認知機能をサポートする方法であって、
赤色、緑色、橙黄色、および紫青色を有する植物材料由来のポリフェノールの相乗的な組み合わせを投与することを含み、
前記組み合わせはBACE1を相乗的に阻害することを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項35に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項35または36に記載の方法。
- 前記投与がアミロイドβプラーク形成の速度を低下させる、請求項35に記載の方法。
- 個人の中枢神経系(CNS)機能をサポートする方法であって、
赤色、緑色、橙黄色、および紫青色を有する植物材料由来のポリフェノールの相乗的な組み合わせを投与することを含み、
前記組み合わせはCDK5を相乗的に阻害することを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項39に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項39または40に記載の方法。
- 前記投与が加齢に伴う認知機能低下を軽減する、請求項39に記載の方法。
- 個人の免疫機能をサポートする方法であって、
赤色、緑色、橙黄色、および紫青色を有する植物材料由来のポリフェノールの相乗的な組み合わせを投与することを含み、
前記組み合わせはJAK1、JAK2、およびJAK3の少なくとも1つを相乗的に阻害することを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項43に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項43または44に記載の方法。
- 前記投与が、関節リウマチ、乾癬、または炎症性腸疾患の症状を軽減する、請求項43に記載の方法。
- BACE1、CD38、CD73、CDK5、JAK1、JAK2、およびJAK3の少なくとも1つを阻害する方法であって、
BACE1、CD38、CD73、CDK5、JAK1、JAK2、およびJAK3の少なくとも1つを、赤色、緑色、橙黄色、および紫青色を有する植物材料由来の複数の化学的に異なるポリフェノールと接触させるステップを含み、
前記植物材料由来の前記化学的に異なるポリフェノールは、BACE1、CD38、CD73、CDK5、JAK1、JAK2、およびJAK3からなる群から選択される少なくとも1つの生化学的マーカーの阻害に関して相乗的な組み合わせであることを特徴とする方法。 - 前記ポリフェノールが前記植物材料の形態で提供される、請求項47に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項47または48に記載の方法。
- 前記接触させるステップがインビボで行われる、請求項47に記載の方法。
- 前記接触させるステップが哺乳動物への経口投与を含む、請求項47に記載の方法。
- 前記組成物が投与されることによって、免疫サポート、代謝サポート、長寿のサポート、中枢神経系(CNS)機能のサポート、炎症反応の軽減、心血管疾患の影響の軽減、およびアミロイドベータプラーク形成率の軽減を提供する、請求項51に記載の方法。
- 哺乳動物におけるBACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSの少なくとも1つの活性に関連する状態を治療する方法であって、
複数の化学的に異なるポリフェノールを、BACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSの少なくとも1つを阻害するのに有効な量で前記哺乳動物に投与することを含むことを特徴とする方法。 - 前記状態が、炎症状態、心血管状態、神経学的状態、代謝状態、および癌である、請求項53に記載の方法。
- 前記複数の化学的に異なるポリフェノールが、赤色、緑色、橙黄色、および紫青色を有する植物材料に由来する、請求項53に記載の方法。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項55に記載の方法。
- 前記ポリフェノールが前記植物材料の形態で提供される、請求項55または56に記載の方法。
- 前記化学的に異なるポリフェノールは、BACE1、CD38、CD73、CDK5、JAK1、JAK2、および/またはJAK3を相乗的に阻害する、請求項53に記載の方法。
- 前記複数の化学的に異なるポリフェノールが前記哺乳動物に経口投与される、請求項53に記載の方法。
- 前記複数の化学的に異なるポリフェノールが50~1,000mgの1日用量で投与される、請求項59に記載の方法。
- 前記哺乳動物に、ビタミン、食物微量元素またはミネラル、ニコチンアミドリボシド、プロバイオティクス、および/またはプレバイオティクスを一緒に投与するステップをさらに含む、請求項53に記載の方法。
- 前記化学的に異なるポリフェノールが、BACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSのうちの少なくとも3つを阻害するのに有効な量で投与される、請求項53に記載の方法。
- 前記化学的に異なるポリフェノールが、BACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSのうちの少なくとも5つを阻害するのに有効な量で投与される、請求項53に記載の方法。
- 前記化学的に異なるポリフェノールが、BACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSのうちの少なくとも10の生化学的マーカーを阻害するのに有効な量で投与される、請求項53に記載の方法。
- 前記化学的に異なるポリフェノールが、BACE1、CD38、CD73、CDK5、JAK1、JAK2、JAK3、ARG-1、ARG-2、SIRT-1、CD39、IDO1、IDO2、NAMPT、PCSK9、CD47、およびカテプシンSを阻害するのに有効な量で投与される、請求項53に記載の方法。
- 健康的な老化をサポートするための化学的に異なる複数のポリフェノールの使用であって、
前記化学的に異なるポリフェノールは、赤色、緑色、橙黄色、紫青色を有する植物材料に存在し、
前記化学的に異なるポリフェノールは、CD38、CD39、CD73、ARG-1、ARG-2、BACE1、CDK5、カテプシンS、JAK1、JAK2、およびJAK3を阻害することを特徴とする使用。 - 前記複数の化学的に異なるポリフェノールが、SIRT-1、IDO1、IDO2、NAMPT、PCSK9、CD47、Keap/Nrf2結合、および/またはACE2/Spike結合をさらに阻害する、請求項66に記載の使用。
- 前記化学的に異なるポリフェノールが、BACE1、CD38、CD73、CDK5、JAK1、JAK2、および/またはJAK3を相乗的に阻害する、請求項66に記載の使用。
- 前記ポリフェノールが植物材料の形態で提供される、請求項66に記載の使用。
- 赤色を有する前記植物材料が、リンゴ抽出物、ザクロ抽出物、トマト粉末、およびビート根粉末からなる群から選択され、緑色を有する前記植物材料が、オリーブ抽出物、ローズマリー抽出物、生コーヒー豆抽出物、およびケール粉末からなる群から選択され、橙黄色を有する前記植物材料が、タマネギ抽出物、ショウガ抽出物、グレープフルーツ抽出物、およびニンジン粉末からなる群から選択され、紫青色を有する前記植物材料が、ブドウ抽出物、ブルーベリー抽出物、スグリ粉末、およびニワトコ粉末からなる群から選択される、請求項66または69に記載の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062970615P | 2020-02-05 | 2020-02-05 | |
US62/970,615 | 2020-02-05 | ||
US202063010183P | 2020-04-15 | 2020-04-15 | |
US63/010,183 | 2020-04-15 | ||
US202063086207P | 2020-10-01 | 2020-10-01 | |
US63/086,207 | 2020-10-01 | ||
PCT/US2021/016670 WO2021158825A1 (en) | 2020-02-05 | 2021-02-04 | Compositions and methods for nutritional supplements |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023512778A true JP2023512778A (ja) | 2023-03-29 |
Family
ID=76862641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022547864A Pending JP2023512778A (ja) | 2020-02-05 | 2021-02-04 | 栄養補助食品の組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US11065295B1 (ja) |
EP (1) | EP4100033A4 (ja) |
JP (1) | JP2023512778A (ja) |
KR (1) | KR20220141310A (ja) |
CN (1) | CN115335068A (ja) |
AU (1) | AU2021216555A1 (ja) |
CA (1) | CA3166761A1 (ja) |
WO (1) | WO2021158825A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116114878A (zh) * | 2022-12-09 | 2023-05-16 | 南京纽邦生物科技有限公司 | 一种植物源组合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1290446C (zh) * | 2002-07-17 | 2006-12-20 | 上海围城自由基生物工程研究所 | 运动营养饮液 |
US20080262081A1 (en) * | 2005-10-14 | 2008-10-23 | Daniel Raederstorff | Novel Use of Nutraceutical Compositions Comprising Resveratrol |
CN101467690A (zh) * | 2007-12-27 | 2009-07-01 | 百泰生物科技股份有限公司 | 含有五种蔬果加工物的营养组合物 |
KR20090078939A (ko) * | 2008-01-16 | 2009-07-21 | 한국화학연구원 | 폴리페놀계 화합물을 함유하는 퇴행성 뇌질환의 예방 또는치료용 조성물 |
US9132162B2 (en) * | 2008-07-31 | 2015-09-15 | Shaklee Corporation | Muscadine compositions with anti-oxidant activity |
EP2418943A4 (en) * | 2009-04-15 | 2012-08-29 | Univ Ohio State Res Found | CURCUMIN ANALOGUES AS DOUBLE JAK2 / STAT3 INHIBITORS AND METHODS FOR THE PREPARATION AND USE THEREOF |
WO2010135589A2 (en) * | 2009-05-20 | 2010-11-25 | Sakura Properties, Llc | Dietary supplement drink for delivery of resveratrol and other polyphenols |
KR20140054066A (ko) * | 2011-07-15 | 2014-05-08 | 뉴서트 사이언시스, 인크. | 대사 경로 조절을 위한 조성물 및 방법 |
CN102697118B (zh) * | 2012-06-09 | 2014-04-30 | 东莞市照燕生物科技有限公司 | 一种抗氧化防癌果蔬汁及其制备工艺 |
US20150190450A1 (en) * | 2014-01-05 | 2015-07-09 | Alice Chang | Ingredient for consumption and application |
TWI759260B (zh) * | 2015-01-02 | 2022-04-01 | 美商梅拉洛伊卡公司 | 多元補充品組成物 |
WO2016149424A1 (en) * | 2015-03-16 | 2016-09-22 | Nature's Sunshine Products, Inc. | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations |
CN107847547A (zh) * | 2015-04-10 | 2018-03-27 | 祖幼立 | 用于靶向癌症治疗的cd38配体‑药物缀合物 |
KR20180020718A (ko) * | 2016-08-19 | 2018-02-28 | 동아대학교 산학협력단 | 이소플라본을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 |
TWI754037B (zh) * | 2017-04-03 | 2022-02-01 | 大江生醫股份有限公司 | 包含植物萃取物的組成物及其減少脂肪之用途 |
US11730749B2 (en) | 2017-05-05 | 2023-08-22 | Plexus Worldwide, Llc | Compositions and methods for improving gut health |
US11007171B2 (en) * | 2017-07-13 | 2021-05-18 | Summit Innovation Labs, LLC | Treatment and prevention of joint disorders |
WO2019092896A1 (ja) | 2017-11-08 | 2019-05-16 | アサヒグループホールディングス株式会社 | アッカーマンシア・ムシニフィラ増殖材 |
CN108541953A (zh) | 2018-04-23 | 2018-09-18 | 张清禹 | 一种具有调节肠道微生物结构并增殖嗜黏蛋白阿卡曼氏菌的组合物 |
-
2021
- 2021-02-04 EP EP21750338.2A patent/EP4100033A4/en active Pending
- 2021-02-04 JP JP2022547864A patent/JP2023512778A/ja active Pending
- 2021-02-04 CN CN202180025495.1A patent/CN115335068A/zh active Pending
- 2021-02-04 US US17/167,998 patent/US11065295B1/en active Active
- 2021-02-04 AU AU2021216555A patent/AU2021216555A1/en active Pending
- 2021-02-04 WO PCT/US2021/016670 patent/WO2021158825A1/en active Search and Examination
- 2021-02-04 KR KR1020227030551A patent/KR20220141310A/ko unknown
- 2021-02-04 CA CA3166761A patent/CA3166761A1/en active Pending
- 2021-06-28 US US17/360,261 patent/US11202816B1/en active Active
- 2021-10-22 US US17/508,543 patent/US11246903B1/en active Active
-
2022
- 2022-01-03 US US17/567,751 patent/US11752188B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3166761A1 (en) | 2021-08-12 |
US11065295B1 (en) | 2021-07-20 |
US20210244786A1 (en) | 2021-08-12 |
US11246903B1 (en) | 2022-02-15 |
KR20220141310A (ko) | 2022-10-19 |
US11752188B2 (en) | 2023-09-12 |
EP4100033A1 (en) | 2022-12-14 |
CN115335068A (zh) | 2022-11-11 |
US20220040251A1 (en) | 2022-02-10 |
WO2021158825A1 (en) | 2021-08-12 |
US20220125871A1 (en) | 2022-04-28 |
AU2021216555A1 (en) | 2022-08-25 |
US11202816B1 (en) | 2021-12-21 |
EP4100033A4 (en) | 2024-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2563991C2 (ru) | Синергические комбинации каротиноидов и полифенолов | |
JP6903594B2 (ja) | 食品、栄養補助食品、化粧品および医薬品に有用な複数の相乗的抗酸化活性を示すフィトコンプレックス | |
KR101682489B1 (ko) | 대사성 증후군의 조절을 위한 스파란터스 인디커스 및 가르시니아 망고스타나 유래의 조성물 | |
US11116747B2 (en) | Compositions comprising proanthocyanidins and oenothein B | |
WO2011108487A1 (ja) | 筋萎縮阻害剤 | |
US9820963B2 (en) | Composition containing lignan compound as active ingredient for preventing or treating cancer | |
US11752188B2 (en) | Compositions and methods for nutritional supplements | |
US10058579B2 (en) | Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity | |
Sui et al. | Metabolites of procyanidins from litchi chinensis pericarp with xanthine oxidase inhibitory effect and antioxidant activity | |
KR20150037024A (ko) | 가중나무 추출물을 유효성분으로 하는 암질환의 치료 또는 예방용 조성물 | |
JP2017145236A (ja) | AGEs関連反応抑制剤、AGEs関連疾患の予防治療用薬剤、並びにサプリメント、機能性食品及び化粧料組成物 | |
US20220257532A1 (en) | Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases | |
US20090048187A1 (en) | Chemopreventive, Anticancer and Anti-Inflammatory Effects of Pinoresinol-Rich Olives | |
JP2016040314A (ja) | 経口用医薬組成物および機能性食品 | |
KR20200034075A (ko) | 토종다래 추출물을 포함하는 미세먼지 및 중금속 관련 항염증 조성물 | |
KR102284073B1 (ko) | 항염증 활성을 갖는 남극 지의류 움빌리카리아 안타티카 추출물 및 이를 함유하는 조성물 | |
KR20180068230A (ko) | 플로레틴 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 결핵 예방 또는 치료용 조성물 | |
Blacks | Effects of Raspberry Consumption on Angiotensin II-induced Hypertension and Expression of Antioxidant and Pro-oxidant Enzymes in the Brain of Rats | |
KR20110062726A (ko) | 캄페라이드 화합물을 유효성분으로 함유하는 항암용 조성물 | |
KR20110032219A (ko) | 7,8,4'-트리하이드록시플라본 화합물을 유효성분으로 함유하는 알러지 질환의 예방 및 치료용 조성물 | |
TW201630598A (zh) | 用於製造與人類凝乳酶的活性相關疾病之預防治療用藥劑之具有黃酮醇骨架之化合物或其藥學上容許之鹽的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221110 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20221003 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240319 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240521 |